1st General Assembly Meeting
TransQST GAM1 took place in Vihti (Finland) in April 2018
The first General Assembly meeting, GAM1, took place on the 25th and 26th of April 2018, in Vihti at Orion Tuohilampi Training Center (Finland). This 2-day meeting was organized as follows: Day 1 – paralel meetings of Organ related WPs with representatives of WP3 (data) and WP4 (modelling), and Day 2 – whole consortium meeting […]
Read moreMore TagUOXF TransQST colleagues won the 2017 NC3Rs Prize
An in silico model that predicts cardiotoxicity awarded in March 2018
On the 12th of March 2018, the National Centre for the 3Rs (NC3Rs) – an organisation dedicated to replacing, refining and reducing the use of animals in research and testing – has awarded its top prize for a research paper on an in silico model that predicts cardiotoxicity developed and reported by the TransQST team […]
Read moreMore TagBoehringer Ingelheim joins the TransQST consortium
Boehringer Ingelheim has joined the consortium, effective since July 2017
The Boehringer Ingelheim (BI) pharmaceutical company made a formal proposal to join the TransQST consortium in June 2017. The TransQST partners found their addition to be an excellent opportunity to complement and extend the coverage of the modeling framework within the particular area of GI toxicity assessment (WP8). SYNAPSE has coordinated the documentation preparation between […]
Read moreMore Tag2nd Workshop
TransQST 2nd Workshop took place in Ludwigshafen (Germany) in September 2017
The 2nd workshop took place on the 28th and 29th of September 2017, in Ludwigshafen at AbbVie premises (Germany). This workshop was scheduled as follow up on the 1st Workshop, January 2017. The goals of this 2nd workshop were focused on the evaluation that all WPs have been doing during these early months of the […]
Read moreMore TagEAB and SAB members
TransQST announces the Ethics and Scientific Advisory Boards members in July 2017
The TransQST consortium is pleased to announce the members of the TransQST Ethics Advisory Board (EAB) and the TransQST Scientific Advisory Board (SAB). To achieve the TransQST objectives, the consortium will use pre-existing data wherever possible but will, on occasion, require access to human/animal biofluid samples and tissue biopsies in order to back-fill data gaps […]
Read moreMore Tag